Abstracts

724 – Comorbidities and Symptoms Associated With Hormone Replacement Therapy Among Women With HIV

Background As the population of women living with HIV (WWH) ages, an increasing number of WWH are experiencing menopause. WWH are at increased risk for menopausal comorbidities, including cardiovascular disease (CVD) and osteoporosis. The objective of this analysis was to examine the association between HRT use and comorbid conditions, metabolic measures, and menopausal symptoms among…

524 – Development of BNT351: A Potent, HIV-1-Neutralizing Antibody With Enhanced Pharmacokinetics

Background Broadly neutralizing antibody (bNAb) 1-18, targeted against the CD4-binding site (CD4bs) on the HIV-1 envelope protein, is a potentially promising tool for shaping future therapeutic and cure-focused clinical strategies against HIV-1. To enhance 1-18’s clinical potential, we introduced half-life-extending LS mutations and evaluated the resulting bNAb, BNT351. Methods Affinity for neonatal Fc receptor (FcRn)…

807 – Effect of Initiating Dolutegravir and Efavirenz-Based ART on the Vaginal Microbiota in Pregnancy

Background Low vaginal bacterial diversity in pregnancy, with Lactobacilli (L) species dominance, is immune protective. Transition to less stable, high diversity community state type (CST) IV (bacterial vaginosis) is linked with inflammation driven preterm birth(PTB). Women living with HIV have high prevalence of non-optimal CSTs and rates of PTB. We hypothesised initiation of antiretroviral therapy(ART)…

577 – HIV-1/Mtb Coinfection Selects for bNAb-Resistant Envelopes Revealed by Droplet PCR Sequencing

Background People living with HIV and active tuberculosis (PWH/TB) generate more broadly potent HIV-1 neutralizing antibodies as compared to those PWH/No TB (Bukola et al.). Enhanced neutralizing antibody responses, together with rapid viral diversification, can favor the emergence of neutralization resistant HIV-1 envelopes. We hypothesize that PWH/TB as compared to PWH/No TB harbor more broadly…

581 – HIV-1 Susceptibility to Lenacapavir Is Not Affected by Capsid Protein Polymorphisms T107A and T107S

Background Lenacapavir (LEN) is the first-in-class twice-yearly long-acting HIV-1 capsid inhibitor approved for treating multidrug-resistant HIV-1, as well as for pre-exposure prophylaxis (PrEP) in people who could benefit from PrEP.  In heavily treatment-experienced people with HIV (PWH), LEN resistance mutations have been observed in the context of LEN functional monotherapy. One such mutation, T107N, is…

592 – Uncovering Occult HBV Replication in People With HIV Using High-Sensitivity HBcrAg Assay

Background People with HIV (PWH) are at increased risk of co-infection with hepatitis B virus (HBV). With the increasing use of antiretroviral regimens that lack anti-HBV activity, the risk of HBV reactivation has become a renewed concern. Occult HBV infection is particularly difficult to identify in patients with isolated anti-HBc, as conventional serological markers often…

594 – Low-Frequency Minority Variants of Hepatitis B Virus Are Associated With Immune Escape Mutations

Background The hepatitis B virus (HBV) is characterised by extensive genetic diversity, including low-frequency minority variants that contribute to disease progression. While these variants represent a critical component of the viral genome pool, their role is often underestimated due to limitations in detection. We therefore characterized low-frequency minority variants associated with drug resistance and immune escape mutations and evaluated their potential…

609 – HIV Status Drives Distinct Immune Pathways of Persistent Portal Hypertension After HCV Cure

Background Persistent portal hypertension after hepatitis C virus (HCV) cure remains a major determinant of prognosis in advanced cirrhosis, yet its immune drivers are poorly defined, particularly in people with HIV (PWH). Hepatic venous pressure gradient (HVPG) is the gold standard for assessing portal hypertension and a strong predictor of outcomes. Despite high rates of…

888 – Optimizing HIV Prevention in South Africa: Spatial Patterns of HIV Incidence From Routine Data

Background Novel HIV prevention methods such as injectable lenacapavir (LEN) will have the greatest impact by reaching populations at the greatest HIV risk in the highest incidence areas. However, incidence is not directly measurable at small geographic scales. We explored relative HIV incidence proxy measures, calculated from routine service delivery data, to identify subdistricts for…